Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...
A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...
Despite the capability of antiretroviral drugs to suppress HIV to undetectable levels, some people living with the human ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
Indian generics would soon become the backbone of the global HIV response. Within two years, the US launched PEPFAR, the ...
Switching from etravirine- to doravirine-containing regimen maintains viral suppression in people with HIV-1 infection, including those with archived resistance to NNRTIs.
The Supreme Court on Tuesday said it would hear on December 3 a plea that has raised concerns over the supply and quality of anti-retroviral (ARV) therapy drugs for treating HIV patients in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback